Non-contrast CT markers were present in 72.1% of patients and independently associated with hematoma expansion, which occurred in 31.8% of patients with FXa inhibitor-associated ICH.
Observational (n=434)
Do non-contrast CT markers predict hematoma expansion and response to andexanet in patients with factor Xa inhibitor-associated intracerebral hemorrhage?
Non-contrast CT markers such as heterogeneous density, hypodensity, and the black hole sign can identify patients at high risk of hematoma expansion in FXa inhibitor-associated ICH.
In this post hoc analysis of the ANNEXa-I trial (n = 434), we evaluated non-contrast computed tomography (NCCT) markers of hematoma expansion (HE) in factor Xa inhibitor (FXai) -associated intracerebral hemorrhage (ICH). At least one NCCT marker was present in 72.1%, and HE (≥12.5 mL or ≥ 35% increase in hematoma volume) occurred in 31.8%. Heterogeneous density, hypodensity, and the black hole sign were independently associated with HE. The effect of andexanet on HE was generally consistent across NCCT marker subgroups. These findings support the utility of NCCT markers for identifying patients at high risk of HE in FXai-associated ICH. ANN NEUROL 2026.
Tanaka et al. (2026) conducted an observational in Factor Xa inhibitor-associated intracerebral hemorrhage (n=434). Non-contrast computed tomography (NCCT) markers was evaluated on Hematoma expansion (≥12.5 mL or ≥ 35% increase in hematoma volume). Non-contrast CT markers were present in 72.1% of patients and independently associated with hematoma expansion, which occurred in 31.8% of patients with FXa inhibitor-associated ICH.